A novel systemically administered toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models

International Journal of Cancer

Volumn 135, Issue 4, 2014, Pages 820-829

  Adlard, Amy L ^a   Dovedi, Simon J ^a   Telfer, Brian A ^a   Koga Yamakawa, Erina ^b   Pollard, Charlotte ^a   Honeychurch, Jamie ^a   Illidge, Timothy M ^a   Murata, Masashi ^b   Robinson, David T ^c   Jewsbury, Philip J ^c   Wilkinson, Robert W ^c,d   Stratford, Ian J ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^c ASTRAZENECA   (United Kingdom)

^d MEDIMMUNE   (United States)

Author keywords

combination therapy; immunotherapy; murine tumor model; radiotherapy; TLR7

Indexed keywords

DSR 6434; INTERFERON REGULATORY FACTOR 7; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CANCER CELL LINE; CANCER RADIOTHERAPY; CD8+ T LYMPHOCYTE; CELL ACTIVATION; COHORT ANALYSIS; COLORECTAL CARCINOMA; CONTROLLED STUDY; CT26 CELL LINE; DISEASE COURSE; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; FIBROSARCOMA; IMMUNE RESPONSE; IMMUNOTHERAPY; INTERFERON INDUCTION; IONIZING RADIATION; KHT CELL LINE; LONG TERM SURVIVAL; LOW DRUG DOSE; LUNG METASTASIS; MOUSE; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME;

COMBINATION THERAPY; IMMUNOTHERAPY; MURINE TUMOR MODEL; RADIOTHERAPY; TLR7;

ADENINE; ANIMALS; B-LYMPHOCYTES; DISEASE MODELS, ANIMAL; FEMALE; HEK293 CELLS; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LUNG; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, KNOCKOUT; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NEOPLASMS; RADIATION, IONIZING; SPLEEN; T-LYMPHOCYTES; TOLL-LIKE RECEPTOR 7;

EID: 84902270524     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28711     Document Type: Article

References (40)

1. Verellen D, De Ridder M, Linthout N, et al. Innovations in image-guided radiotherapy. Nat Rev Cancer 2007; 7: 949-60.
2. Lee LJ, Harris JR,. Innovations in radiation therapy (RT) for breast cancer. Breast 2009; 18 Suppl 3: S103-11.
3. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 345: 638-46.
4. Delaney G, Jacob S, Featherstone C, et al. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer 2005; 104: 1129-37.
5. Reits EA, Hodge JW, Herberts CA, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 2006; 203: 1259-71.
6. Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050-9.
7. Ghiringhelli F, Apetoh L, Tesniere A, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009; 15: 1170-8.
8. Whiteside TL,. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 2006; 16: 3-15.
9. Jarnicki AG, Lysaght J, Todryk S, et al. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol 2006; 177: 896-904.
10. Lee Y, Auh SL, Wang Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 2009; 114: 589-95.
11. Dewan MZ, Galloway AE, Kawashima N, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009; 15: 5379-88.
12. Honeychurch J, Glennie MJ, Johnson PW, et al. Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma. Blood 2003; 102: 1449-57.
13. Mason KA, Ariga H, Neal R, et al. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clin Cancer Res 2005; 11: 361-9.
14. Dovedi SJ, Melis MH, Wilkinson RW, et al. Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma. Blood 2013; 121: 251-9.
15. Gururajan M, Jacob J, Pulendran B,. Toll-like receptor expression and responsiveness of distinct murine splenic and mucosal B-cell subsets. PLoS One 2007; 2: e863.
16. Caron G, Duluc D, Fremaux I, et al. Direct stimulation of human T cells via TLR5 and TLR7/8: flagellin and R-848 up-regulate proliferation and IFN-gamma production by memory CD4+ T cells. J Immunol 2005; 175: 1551-7.
17. Grela F, Aumeunier A, Bardel E, et al. The TLR7 agonist R848 alleviates allergic inflammation by targeting invariant NKT cells to produce IFN-gamma. J Immunol 2011; 186: 284-90.
18. Hart OM, Athie-Morales V, O'Connor GM, et al. TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production. J Immunol 2005; 175: 1636-42.
19. Lund JM, Alexopoulou L, Sato A, et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci U S A 2004; 101: 5598-603.
20. McKenna K, Beignon AS, Bhardwaj N,. Plasmacytoid dendritic cells: linking innate and adaptive immunity. J Virol 2005; 79: 17-27.
21. Hornung V, Rothenfusser S, Britsch S, et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002; 168: 4531-7.
22. Kawai T, Akira S,. TLR signaling. Cell Death Differ 2006; 13: 816-25.
23. Koga-Yamakawa E, Dovedi SJ, Murata M, et al. Intratracheal and oral administration of SM-276001: A selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer. Int J Cancer 2012.
24. Dudek AZ, Yunis C, Harrison LI, et al. First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer. Clin Cancer Res 2007; 13: 7119-25.
25. Nakamura T, Wada H, Kurebayashi H, et al. Synthesis and evaluation of 8-oxoadenine derivatives as potent Toll-like receptor 7 agonists with high water solubility. Bioorg Med Chem Lett 2012.
26. Workman P, Aboagye EO, Balkwill F, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer 2010; 102: 1555-77.
27. Lunt SJ, Telfer BA, Fitzmaurice RJ, et al. Tirapazamine administered as a neoadjuvant to radiotherapy reduces metastatic dissemination. Clin Cancer Res 2005; 11: 4212-6.
28. Gorden KB, Gorski KS, Gibson SJ, et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol 2005; 174: 1259-68.
29. Brown JM, Parker ET,. Host treatments affecting artificial pulmonary metastases: interpretation of loss of radioactively labelled cells from lungs. Br J Cancer 1979; 40: 677-88.
30. Adams S, Kozhaya L, Martiniuk F, et al. Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer. Clin Cancer Res 2012.
31. Wille-Reece U, Flynn BJ, Lore K, et al. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J Exp Med 2006; 203: 1249-58.
32. Weck MM, Grunebach F, Werth D, et al. TLR ligands differentially affect uptake and presentation of cellular antigens. Blood 2007; 109: 3890-4.
33. Belnap LP, Cleveland PH, Colmerauer ME, et al. Immunogenicity of chemically induced murine colon cancers. Cancer Res 1979; 39: 1174-9.
34. Gupta A, Probst HC, Vuong V, et al. Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic cell activation. J Immunol 2012; 189: 558-66.
35. Melief CJ,. Cancer immunotherapy by dendritic cells. Immunity 2008; 29: 372-83.
36. Schon M, Bong AB, Drewniok C, et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 2003; 95: 1138-49.
37. Huang AY, Gulden PH, Woods AS, et al. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci U S A 1996; 93: 9730-5.
38. Mole RH,. Whole body irradiation; radiobiology or medicine? Br J Radiol 1953; 26: 234-41.
39. Demaria S, Kawashima N, Yang AM, et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 2005; 11: 728-34.
40. Rappaport DS, Brown JM,. A study of the mechanism by which localized preinoculation irradiation enhances the rate of lymphatic spread. Radiat Res 1980; 83: 566-78.